Xconomy's Bruce Bigelow has been gleaning as much information as he can lay his hands on concerning the stealth biotech outfit Evoke Pharma in San Diego. Late last year, the developer revealed that it had gained a total of $12.3 million in equity investments from a group of VC investors that includes Domain Associates and Latterell Venture Partners. But CFO Matt D'Onofrio is staying mum about the company's plans, referring the intrepid reporter to the company web site. D'Onofrio says Evoke plans to stay in stealth mode.
For the record, Evoke did put out a release last summer saying it was heading into a clinical trial for a new therapy to treat diabetic gastroparesis, in which the stomach can't contract normally, hindering the way a person digests food. Evoke said it planned discussions with the FDA in October and late-stage trials in 2009.
Then the company--which lists serial biotech entrepreneur Cam Garner as chairman--stopped talking. Bigelow adds that it's still nice to know that VC money continues to flow in this economy.
- check out the report from Xconomy